Al-Khatib, S. M., Han, J. Y., Edwards, R., Bardy, G. H., Bigger, J. T., Buxton, A. E., … Sanders, G. D. (2014). Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator? Int J Cardiol, 172(1), 253–254. https://doi.org/10.1016/j.ijcard.2013.12.278

Al-Khatib, Sana M., Joo Y. Han, Rex Edwards, Gust H. Bardy, J Thomas Bigger, Alfred E. Buxton, Riccardo Cappato, et al. “Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?” Int J Cardiol 172, no. 1 (March 1, 2014): 253–54. https://doi.org/10.1016/j.ijcard.2013.12.278.

Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, et al. Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator? Int J Cardiol. 2014 Mar 1;172(1):253–4.

Al-Khatib, Sana M., et al. “Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?” Int J Cardiol, vol. 172, no. 1, Mar. 2014, pp. 253–54. Pubmed, doi:10.1016/j.ijcard.2013.12.278.

Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton AE, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LYT, Sanders GD. Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator? Int J Cardiol. 2014 Mar 1;172(1):253–254.